Aromatase inhibitors in breast cancer.
暂无分享,去创建一个
[1] H. Lamb,et al. Exemestane: a review of its use in postmenopausal women with advanced breast cancer. , 1998, Drugs.
[2] M. Blankenstein,et al. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. , 1989, European journal of cancer & clinical oncology.
[3] R. Santen,et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. , 1978, The Journal of clinical endocrinology and metabolism.
[4] J. Cuzick,et al. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. , 2001, British journal of cancer.
[5] G. Cocconi,et al. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] F. Cavalli,et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Wolter,et al. Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen , 1994, Cancer.
[8] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[9] R. Casper,et al. Aromatase inhibition for ovarian stimulation: future avenues for infertility management , 2002, Current opinion in obstetrics & gynecology.
[10] D. Tripathy,et al. Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .
[11] T. Key,et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.
[12] S. Bulun,et al. Estrogen production and action. , 2001, Journal of the American Academy of Dermatology.
[13] James N Ingle,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[15] A. Howell,et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.
[16] P. Kellokumpu-Lehtinen,et al. Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen Versus nandrolone decanoate , 1987, Cancer.
[17] L. Kuller,et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. , 1997, Journal of the National Cancer Institute.
[18] P. Dombernowsky,et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Cavalli,et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK) , 1997, European journal of cancer.
[20] P. Dombernowsky,et al. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial , 2004, Breast Cancer Research and Treatment.
[21] M. Morgan,et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Santen,et al. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer , 1982, Cancer research.
[23] J. Dixon,et al. Antiaromatase agents: preclinical data and neoadjuvant therapy. , 2000, Clinical breast cancer.
[24] Yaakov Stern,et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.
[25] M. Piccart,et al. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] A. Howell,et al. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] L. Lipton,et al. Preoperative/neoadjuvant medical therapy for early breast cancer. , 2001, The Lancet. Oncology.
[28] L. Melton,et al. Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] Gynecologists. ACOG (American College of Obstetricians and Gynecologists) committee opinion. Genetic screening for hemoglobinopathies, number 238, July 2000 (replaces number 168, February 1996). Committee on Genetics. , 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[30] L. Rutqvist,et al. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.
[31] R. Santen,et al. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. , 1982, Cancer.
[32] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[33] L. Case,et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Ingle,et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.
[36] N. Boyd,et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Dowsett,et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Dixon,et al. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. , 2002, Cancer control : journal of the Moffitt Cancer Center.
[40] M. Elisaf,et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. , 2001, European journal of cancer.
[41] D. Campos,et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] A. Harris,et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. , 1981, British medical journal.
[43] H. Gundacker,et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] P. Lønning,et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. , 1990, Cancer research.
[45] A. Howell,et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. , 1994, British Journal of Cancer.
[46] F. Cognetti,et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] A. Buzdar,et al. Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials , 1996, Cancer.
[48] L. Demers,et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat , 1998, Breast Cancer Research and Treatment.
[49] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] M. Taskinen,et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Easton,et al. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. , 1987, Cancer research.
[52] M. Dowsett,et al. ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[53] T. Powles,et al. AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA , 1978, The Lancet.
[54] A. Hart,et al. Tamoxifen, serum lipoproteins and cardiovascular risk. , 1988, British Journal of Cancer.
[55] V. Gebski,et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] W. Miller,et al. The importance of local synthesis of estrogen within the breast , 1987, Steroids.
[57] C. Falkson,et al. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] A. Howell,et al. Endocrine-Related Cancer ( 2000 ) 7 131 – 141 Preoperative endocrine therapy for breast cancer , 2000 .
[59] H. Lamb,et al. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. , 1998, Drugs.
[60] D. Hayes,et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] A. Howell,et al. Preoperative endocrine therapy for breast cancer. , 2000, Endocrine-related cancer.
[62] M. Dowsett,et al. LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER , 1984, The Lancet.
[63] T. Powles,et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] I. Tannock,et al. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] P. Lønning,et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. , 1992, British Journal of Cancer.
[66] M. Dowsett,et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[67] P. Lønning. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer , 2004, Breast Cancer Research and Treatment.
[68] Anthony Howell,et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.
[69] A. Howell,et al. Recent advances in endocrine therapy of breast cancer , 1997, BMJ.
[70] K. Boo-Chai. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomised cross‐over trial , 1982 .
[71] L. Wiseman,et al. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. , 1998, Drugs & aging.
[72] W. Boon,et al. Aromatase--a brief overview. , 2002, Annual review of physiology.
[73] P. Goss,et al. Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] I. Smith. Neoadjuvant Endocrine Therapy , 2004 .
[76] N. Zilembo,et al. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[77] C. Mendelson,et al. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[78] P. Lønning,et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. , 1991, British Journal of Cancer.
[79] Leslie J. Browne,et al. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A , 1987, Steroids.
[80] P. Lønning,et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] L. Katz,et al. Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks , 1999 .
[82] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. , 1994, Archives of internal medicine.
[84] J. Dixon,et al. Local endocrine effects of aromatase inhibitors within the breast , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[85] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] F. Alexander,et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.
[87] M. Dowsett,et al. Aromatase and its inhibitors: significance for breast cancer therapy. , 2002, Recent progress in hormone research.
[88] P. Lønning,et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] C. Longcope,et al. Androgen and estrogen metabolism: relationship to obesity. , 1986, Metabolism: clinical and experimental.
[90] U. Chetty,et al. A HUMAN TUMOUR MODEL , 1986, The Lancet.
[91] G. Beatson. On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.
[92] H. Muss,et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] A. Forrest,et al. Significance of aromatase activity in human breast cancer. , 1982, Cancer research.
[94] E. Regnier. Hormonal treatment of advanced breast cancer. , 1956, Minnesota medicine.
[95] R. Santen,et al. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer , 1977, Cancer.
[96] L. Katz,et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. , 2000, JAMA.
[97] A Howell,et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] L. Dirix,et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[100] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[101] M. Mesiti,et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] P. Lønning,et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[103] E. Winer,et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] J. Elmore,et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. , 2001, Journal of the National Cancer Institute.
[105] V. Gebski,et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] G. Hortobagyi,et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.